Cardiogeni (AQSE:CGNI) DeferredTaxAndRevenue: £0.00 Mil (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiogeni DeferredTaxAndRevenue?

Cardiogeni AQSE:CGNI DeferredTaxAndRevenue is £0.00 Mil as of . 20.

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Cardiogeni's current deferred tax and revenue for the quarter that ended in . 20 was £0.00 Mil.

Cardiogeni DeferredTaxAndRevenue Related Terms

Cardiogeni DeferredTaxAndRevenue Historical Data

* Premium members only.

The historical data trend for Cardiogeni's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiogeni DeferredTaxAndRevenue Chart

Cardiogeni Annual Data
Trend
DeferredTaxAndRevenue

Cardiogeni Semi-Annual Data
DeferredTaxAndRevenue
Frequently Asked Questions Learn more about DeferredTaxAndRevenue →
What does a DeferredTaxAndRevenue of £0.00 Mil mean?
Cardiogeni (AQSE:CGNI) has a DeferredTaxAndRevenue of £0.00 Mil as of . 20. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Cardiogeni.
Is Cardiogeni's DeferredTaxAndRevenue too high?
Cardiogeni's current DeferredTaxAndRevenue is £0.00 Mil.
How does Cardiogeni's DeferredTaxAndRevenue compare to ?
Cardiogeni's DeferredTaxAndRevenue of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good DeferredTaxAndRevenue for a Biotechnology company?
A good DeferredTaxAndRevenue depends on the Biotechnology industry context. However, DeferredTaxAndRevenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high DeferredTaxAndRevenue mean?
A high DeferredTaxAndRevenue can signal that a stock is expensive relative to its fundamentals. Deferred tax and revenue represents the current portion of taxes and unearned revenue that are now past due. View historical data on Cardiogeni. Cardiogeni's current DeferredTaxAndRevenue is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiogeni stock overvalued right now?
Cardiogeni (AQSE:CGNI) has a current DeferredTaxAndRevenue of £0.00 Mil. The current DeferredTaxAndRevenue is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is DeferredTaxAndRevenue calculated?
DeferredTaxAndRevenue is calculated from a company's financial statements. For Cardiogeni (AQSE:CGNI), the current DeferredTaxAndRevenue is £0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiogeni Business Description

Comparable Companies
Address Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford upon Avon, GBR, CV37 7GZ
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.